Verified by AISci
Public source attached
Source status for this paper in the current AISci reviewed snapshot.
- Primary source
- ClinicalTrials.gov
- Correction status
- none
- Evidence coverage
- 1 sources / 1 publishers
- Last metadata check
- Jul 19, 2026
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma (NCT04697576)
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma | Phase: PHASE1 | Conditions: Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8
SourceClinicalTrials.govVerified by AISci
Source status for this paper in the current AISci reviewed snapshot.
AI Reading Notes
Structured notes generated from source-linked AISci metadata. Treat them as a reading aid, not a substitute for the paper.
Research Workflow
Recommended next steps for turning this signal into research action.
No reviewed author edge is attached to this output.
No source-confirmed author affiliation is attached.
Controlled AISci Stage A topic for Protein and Drug Design.
Clinical/translation signal: Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
Organization linked by public source evidence.